Rhapontigenin is a natural analog of resveratrol with anticancer, antioxidant, antifungal and antibacterial activities. Rhapontigenin is amechanism-based, potent and selective cytochrome P450 1A1 inactivator (IC50
= 400 nM). Rhapontigenin exhibits 400-fold and 23-fold selectivity for P450 1A1 over P450 1A2 and P450 1B1, respectively.
性状
Solid
IC50 & Target[1][2]
CYP1A1
400 nM (IC50)
体外研究(In Vitro)
Rhapontigenin (0-250 μM; 24 hours) demonstrates concentration-dependent anti-cancer activity with an IC50 115μM in HEP G2 cells.
Rhapontigenin (20 μM; 20 hours) pre-treatment decreases TGF-β triggered increased snail expression in diverse cancer cells.
Rhapontigenin (0-20 μM; 6 hours) inhibits TGF-β-induced expression of N-cadherin, vimentin, and CA9 in a dose-dependent manner.
Rhapontigenin inhibits ADP- and collagen-induced platelet aggregation with IC50 values of 4 and 70 μg/ml, respectively.
Rhapontigenin demonstrates a strong inhibitory activity on the 13-hexosaminidase release induced by DNP-BSA, it exhibits IC50 value of 0.03 mM in RBL 2H3 cells.
Medlife has not independently confirmed the accuracy of these methods. They are for reference only.
Western Blot Analysis
Cell Line:
HeLa, A549,769-P cells
Concentration:
0 μM; 2.5 μM; 5 μM; 10 μM; 20 μM
Incubation Time:
6 hours
Result:
Induced ubiquitination and degradation of HIF-1α.
体内研究(In Vivo)
Rhapontigenin (intraperitoneal injection; 25mg/kg) shows significant protection from death due to pulmonary thrombosis in mice, those samples are orally administered 90 min before tail vein injection of epinephrine and collagen.
Medlife has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Model:
ICR mice
Dosage:
25mg/kg
Administration:
25mg/kg; intraperitoneal injection
Result:
Showed anti-thrombosis activity with 60% protection.